Migraines Accepted Laser Acupuncture Compared in Blood Test of MMP2 and CGRP

StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years later Nov 1, 2025 → Nov 1, 2027
See other at-risk trials from Taichung Veterans General Hospital

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Nov 1, 2025 to Nov 1, 2027
    • Secondary endpoints: details revised at 3 of 10 entries
    • Study description expanded, about 9 words
    • Eligibility criteria expanded, about 3 words
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: May 1, 2025 to Nov 1, 2025
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 1, 2025 to Apr 7, 2025
    v5
  3. Notable Start date: Jan 1, 2025 to Mar 1, 2025
    • Primary completion date: Jan 1, 2025 to May 1, 2025
    • Study completion date: Oct 1, 2027 to Dec 1, 2027
    v4
  4. Notable Start date: Oct 1, 2024 to Jan 1, 2025
    • Primary completion date: Oct 1, 2024 to Jan 1, 2025
    • Secondary endpoints: 8 to 10
    • Study description expanded, about 6 words
    v3
  5. Minor Secondary endpoints revised (8)
    • Study title shortened, about 4 words
    v2
  6. Minor Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Aims: To investigate the efficacy of laser-acupuncture for the severity of primary headache and comorbidities, and the Lab data examination. Methods: In this hospital-based prospective single blind randomized sham-controlled study, patients over 18 years old with primary headache will be randomly divided into two treatment arms including laser-acupuncture and sham-controlled group. The expected laser-acupuncture protocol will be bilateral BL2, GB20, EX-HN5, GB8, LI4, LR3 and midline EX-HN3 in totally eight sessions at the first month. In the sham-laser-acupuncture group, patients will receive eight sessions of laser-acupuncture for free after unblinding. We expected to track patients for at least half year. The diagnosis and classification of headache was evaluated using the ICHD-3 criteria. The severity of headache was evaluated using Migraine Disability Assessment (MIDAS) and headache diary provided by Taiwan Headache Society. The co-primary efficacy end points are change in migraine days per month and variation of MIDAS. The secondary end point is the reducing of the severity of comorbidities including headache related anxiety and depression, and both of the quality of life and sleep. In addition, patients' characteristics will be investigated as follows: 1. Sociodemographic factors (ethnicity, age, sex, body weight, BMI, blood pressure) 2. Headache related parameters (onset, duration, pain scale, current medication for headache, menstrual cycle) 3. Anxiety, evaluate by Hospital Anxiety and Depression Scale (HADS) 4. Depression, evaluate by Beck's Depression Inventory 5. Quality of life, evaluate by 36-Item Short Form Survey (SF-36) 6. Quality of sleep, evaluate by Pittsburgh Sleep Quality Index (PSQI) 7. Aura of headache 8. Episodic or chronic headache (If patient diagnosed as migraine.) 9. Nausea, vomiting, photophobia, phonophobia (If patient diagnosed as migraine.) During the following time, we will need the patient's blood samples four times, each times 20cc, all need 80cc for Lab test of MMP2, CGRP, substance P, beta-endorphin. Importance: In our hospital, we perform laser-acupuncture for patients with headache for several years. A prospective randomized controlled study is the key tools to establish the efficacy of laser-acupuncture for primary headache, and the Lab data with MMP2, CGRP, substance P, beta-endorphin for approval. Look forward to help improve therapeutic strategies in clinical practice.
Trial Details
NCT Number NCT06584409
Lead Sponsor Taichung Veterans General Hospital
Conditions
(from sponsor)
Headache, Migraine
Related terms Migraine Disorders
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov